SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Drug Royalty Corporation (DRI-TSE) -- Ignore unavailable to you. Want to Upgrade?

To: thewiz who wrote (66)7/8/1998 11:12:00 PM
From: Peter Neidhardt  Respond to of 96
 
I suspect that the only way shareholders will benefit from the short to mid-term with this stock is a merger/buyout or some really great news. Other then that, we'll all have to wait a couple of more years till the next great bull market. DRI is slowly sinking....it looks like $2 is going to out of the cards from now on.

One day this puppy will fly!

Peter



To: thewiz who wrote (66)7/9/1998 8:43:00 AM
From: BioInv  Read Replies (1) | Respond to of 96
 
I would be interested in the reasons for seeing this as a"good company"?. Until the last announcement DRI had 80% of its resources in cash. Given that, it was very difficult to justify the $2.50-$2.75 price range which it attained as this was approx. 2 times book and most of the book was cash. I reduced my position at $2.75 but at $1.90 and with two thirds of the resources now invested it looks more interesting. Thanks in advance.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News